This company listing is no longer active
NeuBase Therapeutics Management
Management criteria checks 2/4
NeuBase Therapeutics' CEO is Dietrich Stephan, appointed in Jul 2019, has a tenure of 3.92 years. total yearly compensation is $1.15M, comprised of 46.5% salary and 53.5% bonuses, including company stock and options. directly owns 8.12% of the company’s shares, worth MX$8.87M. The average tenure of the management team and the board of directors is 2 years and 3.7 years respectively.
Key information
Dietrich Stephan
Chief executive officer
US$1.2m
Total compensation
| CEO salary percentage | 46.5% |
| CEO tenure | 3.9yrs |
| CEO ownership | 8.1% |
| Management average tenure | 2yrs |
| Board average tenure | 3.7yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2023 | n/a | n/a | -US$25m |
| Dec 31 2022 | n/a | n/a | -US$30m |
| Sep 30 2022 | US$1m | US$537k | -US$34m |
| Jun 30 2022 | n/a | n/a | -US$33m |
| Mar 31 2022 | n/a | n/a | -US$33m |
| Dec 31 2021 | n/a | n/a | -US$29m |
| Sep 30 2021 | US$2m | US$469k | -US$25m |
| Jun 30 2021 | n/a | n/a | -US$23m |
| Mar 31 2021 | n/a | n/a | -US$18m |
| Dec 31 2020 | n/a | n/a | -US$17m |
| Sep 30 2020 | US$489k | US$441k | -US$17m |
| Jun 30 2020 | n/a | n/a | -US$33m |
| Mar 31 2020 | n/a | n/a | -US$31m |
| Dec 31 2019 | n/a | n/a | -US$29m |
| Sep 30 2019 | US$4m | US$136k | -US$26m |
| Sep 30 2018 | US$25 | n/a | -US$503k |
Compensation vs Market: Dietrich's total compensation ($USD1.15M) is above average for companies of similar size in the MX market ($USD214.14K).
Compensation vs Earnings: Dietrich's compensation has been consistent with company performance over the past year.
CEO
Dietrich Stephan (54 yo)
3.9yrs
Tenure
US$1,154,820
Compensation
Dr. Dietrich A. Stephan, Ph D., serves as Chief Science Advisor at FARMACEUTICALRX LLC. He is the Founder of Lifecode, Inc., and serves as its Chief Executive Officer and President.Dr. Stephan serves as S...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 3.9yrs | US$1.15m | 8.12% MX$ 8.9m | |
| CFO & Secretary | 1.4yrs | US$922.45k | 0.089% MX$ 96.9k | |
| Chief Scientific Officer | 2.5yrs | no data | no data | |
| General Counsel | no data | no data | no data | |
| Chief People Officer | no data | no data | no data | |
| Chief of Preclinical Development & Member of Scientific Advisory Board | no data | no data | no data | |
| Senior Vice President of Corporate Strategy & Business Development | less than a year | no data | no data |
2.0yrs
Average Tenure
54yo
Average Age
Experienced Management: NBSE *'s management team is not considered experienced ( 2 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 3.9yrs | US$1.15m | 8.12% MX$ 8.9m | |
| Chief of Preclinical Development & Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Chairperson | 3.9yrs | US$74.42k | 0.089% MX$ 96.9k | |
| Independent Director | 3.9yrs | US$68.29k | 0% MX$ 0 | |
| Independent Director | 3.9yrs | US$68.38k | 0.13% MX$ 145.2k | |
| Chairperson of Gene Editing Advisory Board & Member of Scientific Advisory Board | less than a year | no data | no data | |
| Member of Gene Editing & Scientific Advisory Board | 3.7yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.6yrs | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Chair of Scientific Advisory Board | no data | no data | no data | |
| Member of Gene Editing & Scientific Advisory Board | 2.7yrs | no data | no data | |
| Member of Gene Editing & Scientific Advisory Board | 2.6yrs | no data | no data |
3.7yrs
Average Tenure
62yo
Average Age
Experienced Board: NBSE *'s board of directors are considered experienced (3.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/06/13 09:16 |
| End of Day Share Price | 2023/03/16 00:00 |
| Earnings | 2023/03/31 |
| Annual Earnings | 2022/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
NeuBase Therapeutics, Inc. is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Thomas Shrader | BTIG |
| Whitney Ijem | Guggenheim Securities, LLC |
| Raghuram Selvaraju | H.C. Wainwright & Co. |